Vorinostat for GVHD Prevention
A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 49 patients (estimated)
- Sponsors
- University of Michigan Comprehensive Cancer Center
- Collaborators
- National Cancer Institute (NCI)
- Tags
- Allogeneic Stem Cell Transplant, Chemotherapy, Histone Deacetylase (HDAC) Inhibitor
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1659
- NCT Identifier
- NCT03842696
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.